Gastrointestinal stromal tumors: Clinicopathological features and outcome-Real-world experience.

IF 2.1 Q3 GASTROENTEROLOGY & HEPATOLOGY
Suriya Nedunchezhian, Vikas Pemmada, Divija Sharma, Athish Shetty, Shiran Shetty, Balaji Musunuri, Jegan Mohan S, Ganesh Bhat
{"title":"Gastrointestinal stromal tumors: Clinicopathological features and outcome-Real-world experience.","authors":"Suriya Nedunchezhian, Vikas Pemmada, Divija Sharma, Athish Shetty, Shiran Shetty, Balaji Musunuri, Jegan Mohan S, Ganesh Bhat","doi":"10.1007/s12664-025-01800-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal stromal tumors (GISTs) are rare neoplasms with diverse clinical profiles and treatment outcomes. This study aims to evaluate the clinical characteristics, treatment modalities and survival outcomes of patients with GISTs treated at a tertiary care hospital in India.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 51 patients with GISTs. Data collected included tumor location, gender, presenting complaints, staging, pathological data, National Institutes of Health (NIH) risk category, treatment offered and outcome. Statistical analyses were performed using SPSS Statistics version 23. Descriptive statistics were used to summarize data and significance was determined with p-values < 0.05.</p><p><strong>Results: </strong>Total 51 patients of GIST were included in this study. Mean age of presentation was 54.38 ± 13.2 and 61% (31/51) patients were male. In this study, most common site of involvement was the small bowel (25/51), followed by stomach (24/51). Most common presenting feature was  pain in abdomen (59% 30/51), followed by gastrointestinal bleed. At diagnosis, localized disease was present in a majority of patients and metastasis was present in only 10% (5/51) of cases. Among non-metastatic disease, spindle cell morphology was predominant (71.7%) and in metastatic disease; mixed cell morphology was more common (60%). Mitotic activity (0.034) and CD34 positivity (p = 0.046) were significantly associated with metastasis. According to NIH risk classification, 33% were low risk, 27% intermediate risk and 39% high risk. Imatinib was given to 75% of patients, while 25% received no drug therapy.</p><p><strong>Conclusion: </strong>GISTs predominantly affect proximal bowel and metastatic disease is very uncommon. Surgical resection with adjuvant tyrosine kinase inhibitor in selected patient is the main treatment with good survival rate. CD34 positivity and mitotic activity was significantly associated with metastasis, indicating its potential as a marker for predicting metastatic spread.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12664-025-01800-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Gastrointestinal stromal tumors (GISTs) are rare neoplasms with diverse clinical profiles and treatment outcomes. This study aims to evaluate the clinical characteristics, treatment modalities and survival outcomes of patients with GISTs treated at a tertiary care hospital in India.

Methods: We conducted a retrospective analysis of 51 patients with GISTs. Data collected included tumor location, gender, presenting complaints, staging, pathological data, National Institutes of Health (NIH) risk category, treatment offered and outcome. Statistical analyses were performed using SPSS Statistics version 23. Descriptive statistics were used to summarize data and significance was determined with p-values < 0.05.

Results: Total 51 patients of GIST were included in this study. Mean age of presentation was 54.38 ± 13.2 and 61% (31/51) patients were male. In this study, most common site of involvement was the small bowel (25/51), followed by stomach (24/51). Most common presenting feature was  pain in abdomen (59% 30/51), followed by gastrointestinal bleed. At diagnosis, localized disease was present in a majority of patients and metastasis was present in only 10% (5/51) of cases. Among non-metastatic disease, spindle cell morphology was predominant (71.7%) and in metastatic disease; mixed cell morphology was more common (60%). Mitotic activity (0.034) and CD34 positivity (p = 0.046) were significantly associated with metastasis. According to NIH risk classification, 33% were low risk, 27% intermediate risk and 39% high risk. Imatinib was given to 75% of patients, while 25% received no drug therapy.

Conclusion: GISTs predominantly affect proximal bowel and metastatic disease is very uncommon. Surgical resection with adjuvant tyrosine kinase inhibitor in selected patient is the main treatment with good survival rate. CD34 positivity and mitotic activity was significantly associated with metastasis, indicating its potential as a marker for predicting metastatic spread.

胃肠道间质瘤:临床病理特征和结果-现实世界的经验。
背景:胃肠道间质瘤(gist)是一种罕见的肿瘤,具有多种临床特征和治疗结果。本研究旨在评估在印度一家三级医院治疗的gist患者的临床特征、治疗方式和生存结果。方法:对51例gist患者进行回顾性分析。收集的数据包括肿瘤位置、性别、主诉、分期、病理数据、美国国立卫生研究院(NIH)的风险类别、提供的治疗和结果。采用SPSS统计软件23进行统计分析。采用描述性统计方法对资料进行汇总,并以p值判定有无显著性。结果:本研究共纳入51例GIST患者。平均发病年龄为54.38±13.2岁,61%(31/51)为男性。在本研究中,最常见的受累部位是小肠(25/51),其次是胃(24/51)。最常见的表现是腹部疼痛(59% 30/51),其次是胃肠道出血。在诊断时,大多数患者存在局限性疾病,只有10%(5/51)的病例存在转移。在非转移性疾病中,梭形细胞形态占主导地位(71.7%),在转移性疾病中;混合细胞形态更为常见(60%)。有丝分裂活性(0.034)和CD34阳性(p = 0.046)与转移显著相关。根据NIH风险分级,低危33%,中危27%,高危39%。75%的患者给予伊马替尼,而25%的患者未接受药物治疗。结论:胃肠道间质瘤主要影响近端肠,转移性疾病非常罕见。手术切除加辅助酪氨酸激酶抑制剂是选择患者的主要治疗方法,生存率较高。CD34阳性和有丝分裂活性与转移显著相关,表明其作为预测转移扩散的标志物的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Indian Journal of Gastroenterology
Indian Journal of Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
3.90
自引率
10.00%
发文量
73
期刊介绍: The Indian Journal of Gastroenterology aims to help doctors everywhere practise better medicine and to influence the debate on gastroenterology. To achieve these aims, we publish original scientific studies, state-of -the-art special articles, reports and papers commenting on the clinical, scientific and public health factors affecting aspects of gastroenterology. We shall be delighted to receive articles for publication in all of these categories and letters commenting on the contents of the Journal or on issues of interest to our readers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信